These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751 [TBL] [Abstract][Full Text] [Related]
4. Basic principles of MR contrast. Nelson KL; Runge VM Top Magn Reson Imaging; 1995; 7(3):124-36. PubMed ID: 7654392 [TBL] [Abstract][Full Text] [Related]
5. MRI susceptometry: image-based measurement of absolute susceptibility of MR contrast agents and human blood. Weisskoff RM; Kiihne S Magn Reson Med; 1992 Apr; 24(2):375-83. PubMed ID: 1569876 [TBL] [Abstract][Full Text] [Related]
6. The magnetic properties of some materials affecting MR images. Josephson L; Bigler J; White D Magn Reson Med; 1991 Dec; 22(2):204-8; discussion 213-5. PubMed ID: 1812347 [TBL] [Abstract][Full Text] [Related]
7. Iron-dextran as a magnetic susceptibility contrast agent: flow-related contrast effects in the T2-weighted spin-echo MRI of normal rat and cat brain. White DL; Aicher KP; Tzika AA; Kucharczyk J; Engelstad BL; Moseley ME Magn Reson Med; 1992 Mar; 24(1):14-28. PubMed ID: 1313524 [TBL] [Abstract][Full Text] [Related]
8. Role of spatial distribution in proton relaxation enhancement by particulate iron oxide. Tanimoto A; Yuasa Y; Stark DD Invest Radiol; 1994 Jun; 29 Suppl 2():S78-80. PubMed ID: 7523329 [No Abstract] [Full Text] [Related]
9. Use of AMI-227 as an oral MR contrast agent. Rogers J; Lewis J; Josephson L Magn Reson Imaging; 1994; 12(4):631-9. PubMed ID: 8057768 [TBL] [Abstract][Full Text] [Related]
10. Superparamagnetic iron oxide--enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Vogl TJ; Hammerstingl R; Schwarz W; Mack MG; Müller PK; Pegios W; Keck H; Eibl-Eibesfeldt A; Hoelzl J; Woessmer B; Bergman C; Felix R Radiology; 1996 Mar; 198(3):881-7. PubMed ID: 8628887 [TBL] [Abstract][Full Text] [Related]
11. Focal nodular hyperplasia of the liver: serial MRI with Gd-DOTA, superparamagnetic iron oxide, and Gd-EOB-DTPA. Kacl GM; Hagspiel KD; Marincek B Abdom Imaging; 1997; 22(3):264-7. PubMed ID: 9107647 [TBL] [Abstract][Full Text] [Related]
12. Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume. Reimer P; Schuierer G; Balzer T; Peters PE Magn Reson Med; 1995 Nov; 34(5):694-7. PubMed ID: 8544689 [TBL] [Abstract][Full Text] [Related]
13. Hepatic in vivo video microscopic study for evaluating experimental and approved magnetic resonance contrast agents. Kruskal JB; Lunderquist A; Clouse ME Invest Radiol; 1994 Jun; 29 Suppl 2():S83-6. PubMed ID: 7928279 [No Abstract] [Full Text] [Related]
16. Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 Tesla. Loubeyre P; De Jaegere T; Bosmans H; Miao Y; Ni Y; Landuyt W; Marchal G J Magn Reson Imaging; 1999 Mar; 9(3):447-53. PubMed ID: 10194716 [TBL] [Abstract][Full Text] [Related]
17. Abdominal MR angiography performed using blood pool contrast agents: comparison of a new superparamagnetic iron oxide nanoparticle and a linear gadolinium polymer. Nolte-Ernsting C; Adam G; Bücker A; Berges S; Bjørnerud A; Günther RW AJR Am J Roentgenol; 1998 Jul; 171(1):107-13. PubMed ID: 9648772 [TBL] [Abstract][Full Text] [Related]
18. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents. Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202 [TBL] [Abstract][Full Text] [Related]
19. Effects of spatial distribution on proton relaxation enhancement by particulate iron oxide. Tanimoto A; Pouliquen D; Kreft BP; Stark DD J Magn Reson Imaging; 1994; 4(5):653-7. PubMed ID: 7526912 [TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]